Rhumbline Advisers Fennec Pharmaceuticals Inc. Transaction History
Rhumbline Advisers
- $103 Billion
- Q1 2024
A detailed history of Rhumbline Advisers transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 20,123 shares of FENC stock, worth $121,341. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,123
Previous 19,883
1.21%
Holding current value
$121,341
Previous $223,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding FENC
# of Institutions
69Shares Held
14.4MCall Options Held
53.2KPut Options Held
83.9K-
Southpoint Capital Advisors LP New York, NY4.08MShares$24.6 Million1.02% of portfolio
-
Sonic Gp LLC Honolulu, HI2.41MShares$14.5 Million35.34% of portfolio
-
Dg Capital Management, LLC New York, NY1.51MShares$9.12 Million10.39% of portfolio
-
Solas Capital Management, LLC Darien, CT1.11MShares$6.69 Million8.43% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.01MShares$6.11 Million0.0% of portfolio
About FENNEC PHARMACEUTICALS INC.
- Ticker FENC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,067,300
- Market Cap $157M
- Description
- Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...